Description Module
The Description Module contains narrative descriptions of the clinical trial, including a brief summary and detailed description. These descriptions provide important information about the study's purpose, methodology, and key details in language accessible to both researchers and the general public.
Description Module path is as follows:
Study -> Protocol Section -> Description Module
Description Module
Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2025-12-25 @ 12:32 AM
NCT ID:
NCT07172867
Brief Summary:
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
Detailed Description:
The purpose of this study is to evaluate the efficacy and safety of ofirnoflast in combination with semaglutide in comparison to semaglutide alone in obese participants with T2DM.
This study is a randomized, double-blind, placebo-controlled, parallel-group clinical trial.
* The study duration will be up to 28 weeks.
* The screening period will be up to 4 weeks
* The treatment duration will be 12 weeks.
* The follow-up period will be 12 weeks
* The visit frequency will be every 4 weeks during the treatment phase of the study.
* There will be an anticipated 7 scheduled clinic visits, including 1 screening visit and 2 follow-up visits.
Study:
NCT07172867
Study Brief:
Protocol Section:
NCT07172867